Last updated at 28 Jun 2024 09:38 PM
Director
DIN: 08251943
Shalini Rahul Purwar is currently associated with 2 companies in various capacities such as Director and Individual Promoter. They serve as a Director at IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 08251943.Shalini Rahul Purwar is currently involved in 2 different roles. Their most recent position is with IMMUNOACT RESEARCH FOUNDATION as a Director. The first company Shalini Rahul Purwar was appointed to as a director was IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED. Shalini Rahul Purwar is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
Shalini Rahul Purwar is currently associated with 2 companies in various capacities such as Director and Individual Promoter. They serve as a Director at IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 08251943.Shalini Rahul Purwar is currently involved in 2 different roles. Their most recent position is with IMMUNOACT RESEARCH FOUNDATION as a Director. The first company Shalini Rahul Purwar was appointed to as a director was IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED. Shalini Rahul Purwar is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
3
Female
India
Gain instant access to verified contact details.
Current Companies (2)
Current LLPs (0)
Past Companies (0)
1y 6m 9 Months Interval
| Company Name | Designation | Date of Appointment |
|---|---|---|
| IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED | Director | 08-Oct-2018 |
| IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED | Individual Promoter | 08-Oct-2018 |
| IMMUNOACT RESEARCH FOUNDATION | Director | 09-Nov-2023 |